Group 1 - Compugen Ltd. (NASDAQ: CGEN) is an immuno-oncology biotech utilizing its Unigen platform for discovering immune checkpoints, drug candidates, and biomarkers [1] - The Unigen platform is based on Artificial Intelligence and Machine Learning technologies [1] Group 2 - The article does not provide any financial performance data or specific investment recommendations related to Compugen Ltd. [2][3]